{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:23:06Z","timestamp":1792110186390,"version":"4.4.0"},"reference-count":165,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la recherche sur le cancer","doi-asserted-by":"publisher","award":["PJA 20161204650"],"award-info":[{"award-number":["PJA 20161204650"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Peroxisome proliferator-activated receptors (PPARs) belong to the family of ligand-activated nuclear receptors. The PPAR family consists of three subtypes encoded by three separate genes: PPAR\u03b1 (NR1C1), PPAR\u03b2\/\u03b4 (NR1C2), and PPAR\u03b3 (NR1C3). PPARs are critical regulators of metabolism and exhibit tissue and cell type-specific expression patterns and functions. Specific PPAR ligands have been proposed as potential therapies for a variety of diseases such as metabolic syndrome, cancer, neurogenerative disorders, diabetes, cardiovascular diseases, endometriosis, and retinopathies. In this review, we focus on the knowledge of PPAR function in angiogenesis, a complex process that plays important roles in numerous pathological conditions for which therapeutic use of PPAR modulation has been suggested.<\/jats:p>","DOI":"10.3390\/ijms21165723","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:25:03Z","timestamp":1597044303000},"page":"5723","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["PPARs and Angiogenesis\u2014Implications in Pathology"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0707","authenticated-orcid":false,"given":"Nicole","family":"Wagner","sequence":"first","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CNRS, INSERM, iBV, 06107 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-7760","authenticated-orcid":false,"given":"Kay-Dietrich","family":"Wagner","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CNRS, INSERM, iBV, 06107 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pharmthera.2009.12.001","article-title":"Peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) acts as regulator of metabolism linked to multiple cellular functions","volume":"125","author":"Wagner","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17042","DOI":"10.1074\/jbc.274.24.17042","article-title":"Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2","volume":"274","author":"Hla","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1042\/BST20110643","article-title":"PPARs and angiogenesis","volume":"39","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lagan\u00e0, A.S., Vitale, S.G., Nigro, A., Sofo, V., Salmeri, F.M., Rossetti, P., Rapisarda, A.M., La Vignera, S., Condorelli, R.A., and Rizzo, G. (2016). Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17070999"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vitale, S.G., Lagan\u00e0, A.S., Nigro, A., La Rosa, V.L., Rossetti, P., Rapisarda, A.M., La Vignera, S., Condorelli, R.A., Corrado, F., and Buscema, M. (2016). Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR Res., 2016.","DOI":"10.1155\/2016\/6517313"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2005.03.003","article-title":"PPARs: Therapeutic targets for metabolic disease","volume":"26","author":"Berger","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Michalik, L., and Wahli, W. (2008). PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res., 2008.","DOI":"10.1155\/2008\/134059"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., and Wahli, W. (2020). Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells, 9.","DOI":"10.3390\/cells9071638"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1074\/jbc.274.13.9116","article-title":"Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo","volume":"274","author":"Xin","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.HYP.0000035522.63647.D3","article-title":"Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands","volume":"40","author":"Goetze","year":"2002","journal-title":"Hypertension"},{"key":"ref_11","first-page":"693","article-title":"Loss of PPAR\u03b3 in endothelial cells leads to impaired angiogenesis","volume":"129","author":"Akinrinade","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"He, Q., Pang, R., Song, X., Chen, J., Chen, H., Chen, B., Hu, P., and Chen, M. (2008). Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARgamma Dependent and Independent Mechanisms. PPAR Res., 2008.","DOI":"10.1155\/2008\/649808"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10456-008-9118-0","article-title":"PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis","volume":"11","author":"Aljada","year":"2008","journal-title":"Angiogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.08305FP","article-title":"Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells","volume":"111","author":"Park","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13503","DOI":"10.1074\/jbc.M510357200","article-title":"Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells","volume":"281","author":"Kim","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/cvr\/cvp400","article-title":"PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium","volume":"86","author":"Scoditti","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_17","first-page":"217","article-title":"The MAPK-dependent regulation of the Jagged\/Notch gene expression by VEGF, bFGF or PPAR gamma mediated angiogenesis in HUVEC","volume":"61","author":"Polus","year":"2010","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11010-011-0989-9","article-title":"Anti-angiogenic action of PPAR\u03b3 ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation","volume":"358","author":"Kim","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jsbmb.2011.12.014","article-title":"Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma","volume":"129","author":"Fujii","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10456-005-9027-4","article-title":"PPAR gamma represses VEGF expression in human endometrial cells: Implications for uterine angiogenesis","volume":"8","author":"Peeters","year":"2005","journal-title":"Angiogenesis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.2337\/diabetes.53.5.1222","article-title":"Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3","volume":"53","author":"Sassa","year":"2004","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.18388\/abp.2000_3967","article-title":"Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages","volume":"47","author":"Jozkowicz","year":"2000","journal-title":"Acta Biochim. Pol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/bbrc.2000.2665","article-title":"Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells","volume":"271","author":"Yamakawa","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cardiores.2007.01.010","article-title":"PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts","volume":"74","author":"Chintalgattu","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23534","DOI":"10.1074\/jbc.M200172200","article-title":"Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells","volume":"277","author":"Fauconnet","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1158\/0008-5472.CAN-03-2760","article-title":"Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines","volume":"64","author":"Stephen","year":"2004","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.ATV.0000250972.83623.61","article-title":"Activation of PPARbeta\/delta induces endothelial cell proliferation and angiogenesis","volume":"27","author":"Piqueras","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Faulkner, A., Lynam, E., Purcell, R., Jones, C., Lopez, C., Board, M., Wagner, K.D., Wagner, N., Carr, C., and Wheeler-Jones, C. (2020). Context-dependent regulation of endothelial cell metabolism: Differential effects of the PPAR\u03b2\/\u03b4 agonist GW0742 and VEGF-A. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63900-0"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wagner, K.D., Du, S., Martin, L., Leccia, N., Michiels, J.F., and Wagner, N. (2019). Vascular PPAR\u03b2\/\u03b4 Promotes Tumor Angiogenesis and Progression. Cells, 8.","DOI":"10.3390\/cells8121623"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCRESAHA.108.176057","article-title":"Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells","volume":"103","author":"He","year":"2008","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cvr\/cvp365","article-title":"PPARdelta and PGC1alpha act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress","volume":"85","author":"Ali","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00403-010-1091-y","article-title":"PPAR\u03b4 agonists suppress angiogenesis in a VEGFR2-dependent manner","volume":"303","author":"Meissner","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/jcb.24063","article-title":"The PPAR\u03b4 ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPAR\u03b4","volume":"113","author":"Park","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0006-2952(01)00822-X","article-title":"Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin","volume":"62","author":"Jaradat","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1073\/pnas.87.17.6624","article-title":"A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin","volume":"87","author":"Good","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-1-4615-0193-0_52","article-title":"Regulation of CD36 expression in human melanoma cells","volume":"507","author":"Chen","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.taap.2006.10.013","article-title":"Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells","volume":"218","author":"Huang","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2005.05.018","article-title":"Tissue factor and tumor: Clinical and laboratory aspects","volume":"364","author":"Meye","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"ref_39","first-page":"106","article-title":"Role of peroxisome proliferator-activated receptor alpha and gamma in antiangiogenic effect of pomegranate peel extract","volume":"19","author":"Dana","year":"2016","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00018-003-2322-6","article-title":"Fenofibrate inhibits angiogenesis in vitro and in vivo","volume":"60","author":"Varet","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., and Michalik, L. (2011). Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPAR\u03b1 mediated mechanism. PLoS ONE, 6.","DOI":"10.1371\/annotation\/a392bbef-b0ec-4c70-b403-74a7bad85178"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2008.05.055","article-title":"Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation","volume":"203","author":"Kitajima","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.0303-6987.2005.00345.x","article-title":"Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors","volume":"32","author":"Nijsten","year":"2005","journal-title":"J. Cutan. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kaipainen, A., Kieran, M.W., Huang, S., Butterfield, C., Bielenberg, D., Mostoslavsky, G., Mulligan, R., Folkman, J., and Panigrahy, D. (2007). PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000260"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1073\/pnas.0711281105","article-title":"PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition","volume":"105","author":"Panigrahy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1535-7163.MCT-06-0722","article-title":"Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer","volume":"6","author":"Yokoyama","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1074\/jbc.M109.081554","article-title":"The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated","volume":"285","author":"Pozzi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-13-1928","article-title":"PPAR\u03b1 activation can help prevent and treat non-small cell lung cancer","volume":"74","author":"Skrypnyk","year":"2014","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wu, L., Wang, W., Dai, M., Li, H., Chen, C., and Wang, D. (2019). PPAR\u03b1 ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6379-5"},{"key":"ref_50","first-page":"348","article-title":"Standardized","volume":"18","author":"Seifabadi","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbalip.2013.04.012","article-title":"The PPAR\u03b1 agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism","volume":"1831","author":"Huang","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.1073\/pnas.0705505104","article-title":"Transcriptional network governing the angiogenic switch in human pancreatic cancer","volume":"104","author":"Abdollahi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/sj.emboj.7601803","article-title":"Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice","volume":"26","author":"Rieck","year":"2007","journal-title":"EMBO J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s10620-008-0465-x","article-title":"The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers","volume":"54","author":"Yoshinaga","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zuo, X., Xu, W., Xu, M., Tian, R., Moussalli, M.J., Mao, F., Zheng, X., Wang, J., Morris, J.S., and Gagea, M. (2017). Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2.","DOI":"10.1172\/jci.insight.91419"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wagner, K.D., Vukolic, A., Baudouy, D., Michiels, J.F., and Wagner, N. (2016). Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta\/Delta Leads to Rapid Cardiac Hypertrophy. PPAR Res., 2016.","DOI":"10.1155\/2016\/7631085"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/ol.2013.1650","article-title":"Correlation between TSP-1, TGF-\u03b2 and PPAR-\u03b3 expression levels and glioma microvascular density","volume":"7","author":"Zhang","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","article-title":"PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis","volume":"110","author":"Panigrahy","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1541-7786.541.2.10","article-title":"Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510","volume":"2","author":"Huang","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1593\/neo.04601","article-title":"PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer","volume":"7","author":"Keshamouni","year":"2005","journal-title":"Neoplasia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.onc.1209267","article-title":"Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1\/CIP1","volume":"25","author":"Copland","year":"2006","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.22854","article-title":"Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers","volume":"110","author":"Xin","year":"2007","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00432-011-0993-1","article-title":"Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers","volume":"137","author":"Yokoyama","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3748\/wjg.15.441","article-title":"Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition","volume":"15","author":"Dong","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/cas.13650","article-title":"Synergy between peroxisome proliferator-activated receptor \u03b3 agonist and radiotherapy in cancer","volume":"109","author":"Huang","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/0008-5472.CAN-12-4018","article-title":"SOCS3 transactivation by PPAR\u03b3 prevents IL-17-driven cancer growth","volume":"73","author":"Berger","year":"2013","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1038\/onc.2015.475","article-title":"Tumor suppressor control of the cancer stem cell niche","volume":"35","author":"Kramer","year":"2016","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-09-2067","article-title":"Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis","volume":"69","author":"Tian","year":"2009","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1158\/0008-5472.CAN-18-0912","article-title":"Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPAR\u03b3 Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth","volume":"78","author":"Pich","year":"2018","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wagner, N., and Wagner, K.D. (2020). PPAR Beta\/Delta and the Hallmarks of Cancer. Cells, 9.","DOI":"10.3390\/cells9051133"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2005.03.039","article-title":"PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells","volume":"183","author":"Pistrosch","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mce.2013.07.011","article-title":"Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPAR\u03b3","volume":"381","author":"Biscetti","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000335214","article-title":"Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression","volume":"49","author":"Ashoff","year":"2012","journal-title":"J. Vasc. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopha.2007.06.014","article-title":"Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice","volume":"62","author":"Huang","year":"2008","journal-title":"Biomed. Pharmacother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/nature06613","article-title":"HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha","volume":"451","author":"Arany","year":"2008","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2005.10.047","article-title":"Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models","volume":"188","author":"Kasai","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_77","first-page":"S9","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha, improves myocardial capillary density in diabetic rats","volume":"62","author":"Salehi","year":"2012","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4149\/gpb_2012_033","article-title":"Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats","volume":"31","author":"Salehi","year":"2012","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1159\/000479999","article-title":"PPAR\u03b1 Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway","volume":"42","author":"Deng","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2006.03.114","article-title":"Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia","volume":"1093","author":"Chu","year":"2006","journal-title":"Brain Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCRESAHA.110.235390","article-title":"Early atheroma-derived agonists of peroxisome proliferator-activated receptor-\u03b3 trigger intramedial angiogenesis in a smooth muscle cell-dependent manner","volume":"109","author":"Gomez","year":"2011","journal-title":"Circ. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4070\/kcj.2017.0029","article-title":"Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET\/CT","volume":"48","author":"Choo","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_84","first-page":"881","article-title":"Effect of pioglitazone on insulin resistance, progression of atherosclerosis and clinical course of coronary heart disease","volume":"70","author":"Skochko","year":"2017","journal-title":"Wiad. Lek."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1055\/s-2005-870322","article-title":"Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes","volume":"37","author":"Forst","year":"2005","journal-title":"Horm. Metab. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.atherosclerosis.2014.03.035","article-title":"PPAR\u03b3 activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia","volume":"234","author":"Campia","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Marder, W., Khalatbari, S., Myles, J.D., Hench, R., Lustig, S., Yalavarthi, S., Parameswaran, A., Brook, R.D., and Kaplan, M.J. (2013). The peroxisome proliferator activated receptor-\u03b3 pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J. Am. Heart Assoc., 2.","DOI":"10.1161\/JAHA.113.000441"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.atherosclerosis.2006.11.007","article-title":"Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men","volume":"194","author":"Ryan","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2015.03.021","article-title":"Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes","volume":"170","author":"Erdmann","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/dom.12455","article-title":"Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: Pooled findings from three randomized phase III trials","volume":"17","author":"Henry","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ahj.2013.05.013","article-title":"Evaluation of the dual peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial","volume":"166","author":"Lincoff","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Deeg, M.A., and Tan, M.H. (2008). Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Res., 2008.","DOI":"10.1155\/2008\/520465"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1152\/ajpendo.00581.2007","article-title":"Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle","volume":"295","author":"Gaudel","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00424-009-0676-9","article-title":"Peroxisome proliferator-activated receptor beta activation promotes myonuclear accretion in skeletal muscle of adult and aged mice","volume":"458","author":"Giordano","year":"2009","journal-title":"Pflugers Arch."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"21401","DOI":"10.1073\/pnas.0909131106","article-title":"The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle","volume":"106","author":"Chinsomboon","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/eurheartj\/ehr365","article-title":"Peroxisome proliferator-activated receptor-\u03b4 activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine networks","volume":"34","author":"Han","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2012.02.005","article-title":"Role of peroxisome proliferator-activated receptor \u03b2 agonist on angiogenesis in hindlimb ischemic diabetic rats","volume":"26","author":"Khazaei","year":"2012","journal-title":"J. Diabetes Complicat."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Khazaei, M., Salehi, E., and Rashidi, B. (2012). Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Int. J. Pept., 2012.","DOI":"10.1155\/2012\/637212"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jep.2018.08.032","article-title":"Naoxintong restores collateral blood flow in a murine model of hindlimb ischemia through PPAR\u03b4-dependent mechanism","volume":"227","author":"Chen","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cvr\/cvp106","article-title":"Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin","volume":"83","author":"Wagner","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wagner, K.D., Vukolic, A., Baudouy, D., Michiels, J.F., and Wagner, N. (2018). Erratum to \u201cInducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta\/Delta Leads to Rapid Cardiac Hypertrophy\u201d. PPAR Res., 2018.","DOI":"10.1155\/2018\/5480829"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Park, J.R., Ahn, J.H., Jung, M.H., Koh, J.S., Park, Y., Hwang, S.J., Jeong, Y.H., Kwak, C.H., Lee, Y.S., and Seo, H.G. (2016). Effects of Peroxisome Proliferator-Activated Receptor-\u03b4 Agonist on Cardiac Healing after Myocardial Infarction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148510"},{"key":"ref_107","first-page":"2309","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization","volume":"41","author":"Murata","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.exer.2004.10.009","article-title":"Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand","volume":"80","author":"Sarayba","year":"2005","journal-title":"Exp. Eye Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1073\/pnas.1401191111","article-title":"Cytochrome P450-generated metabolites derived from \u03c9-3 fatty acids attenuate neovascularization","volume":"111","author":"Yanai","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Sapieha, P., Stahl, A., Chen, J., Seaward, M.R., Willett, K.L., Krah, N.M., Dennison, R.J., Connor, K.M., Aderman, C.M., and Liclican, E. (2011). 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of \u03c9-3 polyunsaturated fatty acids. Sci. Transl. Med., 3.","DOI":"10.1126\/scitranslmed.3001571"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCRESAHA.110.221317","article-title":"Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy","volume":"107","author":"Stahl","year":"2010","journal-title":"Circ. Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Li, Z., He, T., Du, K., Xing, Y.Q., Run, Y.M., Yan, Y., and Shen, Y. (2014). Inhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-\u03b3 and down-regulation of VEGFR-2 expression. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085824"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3892\/mmr.2015.4678","article-title":"Application of recombinant peroxisome proliferator-activated receptor-\u03b3 coactivator-1\u03b1 mediates neovascularization in the retina","volume":"13","author":"Jiang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.yjmcc.2003.10.016","article-title":"Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: A possible role for peroxisome proliferator-activated receptors","volume":"36","author":"Pola","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2337\/db07-0765","article-title":"Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism","volume":"57","author":"Biscetti","year":"2008","journal-title":"Diabetes"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1091581810376674","article-title":"WY-14 643, a selective PPAR{alpha} agonist, induces proinflammatory and proangiogenic responses in human ocular cells","volume":"29","author":"Zhang","year":"2010","journal-title":"Int. J. Toxicol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ebiom.2016.09.025","article-title":"Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis","volume":"13","author":"Gong","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.intimp.2017.08.027","article-title":"The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells","volume":"52","author":"Ouchi","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Capozzi, M.E., Savage, S.R., McCollum, G.W., Hammer, S.S., Ramos, C.J., Yang, R., Bretz, C.A., and Penn, J.S. (2020). The peroxisome proliferator-activated receptor-\u03b2\/\u03b4 antagonist GSK0660 mitigates retinal cell inflammation and leukostasis. Exp. Eye Res., 190.","DOI":"10.1016\/j.exer.2019.107885"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1167\/iovs.13-11608","article-title":"Peroxisome proliferator-activated receptor-\u03b2\/\u03b4 regulates angiogenic cell behaviors and oxygen-induced retinopathy","volume":"54","author":"Capozzi","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gu, Y., Li, X., He, T., Jiang, Z., Hao, P., and Tang, X. (2014). The Antifibrosis Effects of Peroxisome Proliferator-Activated Receptor \u03b4 on Rat Corneal Wound Healing after Excimer Laser Keratectomy. PPAR Res., 2014.","DOI":"10.1155\/2014\/464935"},{"key":"ref_124","first-page":"568","article-title":"RNA-seq identifies a role for the PPAR\u03b2\/\u03b4 inverse agonist GSK0660 in the regulation of TNF\u03b1-induced cytokine signaling in retinal endothelial cells","volume":"21","author":"Savage","year":"2015","journal-title":"Mol. Vis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.18632\/aging.101031","article-title":"PPAR\u03b2\/\u03b4 selectively regulates phenotypic features of age-related macular degeneration","volume":"8","author":"Choudhary","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2001.4847","article-title":"Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2","volume":"283","author":"Tsubouchi","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1172\/JCI9652","article-title":"15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats","volume":"106","author":"Kawahito","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/art.11351","article-title":"Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma","volume":"48","author":"Cuzzocrea","year":"2003","journal-title":"Arthritis Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.20792","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs","volume":"52","author":"Kobayashi","year":"2005","journal-title":"Arthritis Rheumatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/art.22726","article-title":"The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways","volume":"56","author":"Boileau","year":"2007","journal-title":"Arthritis Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ajpath.2012.12.012","article-title":"Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype","volume":"182","author":"Vasheghani","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/annrheumdis-2014-205743","article-title":"PPAR\u03b3 deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage","volume":"74","author":"Vasheghani","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.19.9.2094","article-title":"Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction","volume":"19","author":"Jackson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/keh423","article-title":"Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study","volume":"44","author":"Bongartz","year":"2005","journal-title":"Rheumatology"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ormseth, M.J., Oeser, A.M., Cunningham, A., Bian, A., Shintani, A., Solus, J., Tanner, S., and Stein, C.M. (2013). Peroxisome proliferator-activated receptor \u03b3 agonist effect on rheumatoid arthritis: A randomized controlled trial. Arthritis Res. Ther., 15.","DOI":"10.1186\/ar4290"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/art.38686","article-title":"Reversing vascular dysfunction in rheumatoid arthritis: Improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor \u03b3 agonist therapy","volume":"66","author":"Ormseth","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yue, M., Zeng, N., Xia, Y., Wei, Z., and Dai, Y. (2018). Morin Exerts Anti-Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor-\u03b3. Mol. Nutr. Food Res., 62.","DOI":"10.1002\/mnfr.201800202"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/ard.2003.015008","article-title":"Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis","volume":"63","author":"Okamoto","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_141","first-page":"323","article-title":"Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis","volume":"23","author":"Okamoto","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00296-013-2766-4","article-title":"Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: A pilot study","volume":"34","author":"Shirinsky","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jri.2007.05.004","article-title":"Role of nuclear receptors and their ligands in human trophoblast invasion","volume":"77","author":"Fournier","year":"2008","journal-title":"J. Reprod. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.placenta.2006.12.006","article-title":"Involvement of PPARgamma in human trophoblast invasion","volume":"28","author":"Fournier","year":"2007","journal-title":"Placenta"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.placenta.2006.04.009","article-title":"PPARs and the placenta","volume":"28","author":"Fournier","year":"2007","journal-title":"Placenta"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/plac.2002.0855","article-title":"Expression of PPAR and RXR isoforms in the developing rat and human term placentas","volume":"23","author":"Wang","year":"2002","journal-title":"Placenta"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1530\/rep.0.1250817","article-title":"Differential expression of peroxisome proliferator-activated receptor delta at implantation sites and in decidual cells of rat uterus","volume":"125","author":"Ding","year":"2003","journal-title":"Reproduction"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mrd.10348","article-title":"Peroxisome proliferator-activated receptor delta expression and regulation in mouse uterus during embryo implantation and decidualization","volume":"66","author":"Ding","year":"2003","journal-title":"Mol. Reprod. Dev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1097-2765(00)80209-9","article-title":"PPAR gamma is required for placental, cardiac, and adipose tissue development","volume":"4","author":"Barak","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","article-title":"PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance","volume":"4","author":"Kubota","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1210\/en.2010-0131","article-title":"PPARgamma in placental angiogenesis","volume":"151","author":"Nadra","year":"2010","journal-title":"Endocrinology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1073\/pnas.0400356101","article-title":"Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse","volume":"101","author":"Imai","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/HYPERTENSIONAHA.111.179440","article-title":"Evidence implicating peroxisome proliferator-activated receptor-\u03b3 in the pathogenesis of preeclampsia","volume":"58","author":"McCarthy","year":"2011","journal-title":"Hypertension"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3892\/mmr.2017.6903","article-title":"Peroxisome proliferator-activated receptor \u03b3 mediates porcine placental angiogenesis through hypoxia inducible factor-, vascular endothelial growth factor- and angiopoietin-mediated signaling","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/humrep\/deu035","article-title":"Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-\u03b3 by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions","volume":"29","author":"Nenicu","year":"2014","journal-title":"Hum. Reprod."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1073\/pnas.012610299","article-title":"Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer","volume":"99","author":"Barak","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"37770","DOI":"10.1074\/jbc.M706577200","article-title":"Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success","volume":"282","author":"Wang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/bdrb.21052","article-title":"Effect of PPAR\u03b2\/\u03b4 agonist on the placentation and embryo-fetal development in rats","volume":"98","author":"Nishimura","year":"2013","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd1226","article-title":"Therapeutic angiogenesis in cardiovascular disease","volume":"2","author":"Simons","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_160","unstructured":"Abcouwer, S.F. (2013). Angiogenic Factors and Cytokines in Diabetic Retinopathy. J. Clin. Cell. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Rocha, A.L., Reis, F.M., and Taylor, R.N. (2013). Angiogenesis and endometriosis. Obstet. Gynecol. Int., 2013.","DOI":"10.1155\/2013\/859619"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","article-title":"The pathogenic role of angiogenesis in rheumatoid arthritis","volume":"18","author":"Elshabrawy","year":"2015","journal-title":"Angiogenesis"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1002\/cncr.27526","article-title":"A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies","volume":"118","author":"Pishvaian","year":"2012","journal-title":"Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","article-title":"Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma","volume":"96","author":"Demetri","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/16\/5723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:58:40Z","timestamp":1760176720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/16\/5723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":165,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["ijms21165723"],"URL":"https:\/\/doi.org\/10.3390\/ijms21165723","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}